AbbVie Inc (ABBV)
164.93
-2.36
(-1.41%)
USD |
NYSE |
Apr 26, 09:36
AbbVie Enterprise Value: 342.12B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 342.12B |
| April 24, 2024 | 343.02B |
| April 23, 2024 | 346.09B |
| April 22, 2024 | 343.18B |
| April 19, 2024 | 340.56B |
| April 18, 2024 | 337.47B |
| April 17, 2024 | 336.75B |
| April 16, 2024 | 333.73B |
| April 15, 2024 | 332.19B |
| April 12, 2024 | 333.27B |
| April 11, 2024 | 342.53B |
| April 10, 2024 | 345.19B |
| April 09, 2024 | 347.15B |
| April 08, 2024 | 346.55B |
| April 05, 2024 | 346.91B |
| April 04, 2024 | 343.20B |
| April 03, 2024 | 359.85B |
| April 02, 2024 | 365.79B |
| April 01, 2024 | 365.91B |
| March 28, 2024 | 368.28B |
| March 27, 2024 | 365.19B |
| March 26, 2024 | 363.14B |
| March 25, 2024 | 361.97B |
| March 22, 2024 | 361.83B |
| March 21, 2024 | 360.16B |
| Date | Value |
|---|---|
| March 20, 2024 | 357.98B |
| March 19, 2024 | 363.97B |
| March 18, 2024 | 361.90B |
| March 15, 2024 | 360.83B |
| March 14, 2024 | 366.69B |
| March 13, 2024 | 364.32B |
| March 12, 2024 | 366.20B |
| March 11, 2024 | 363.92B |
| March 08, 2024 | 362.54B |
| March 07, 2024 | 365.58B |
| March 06, 2024 | 366.44B |
| March 05, 2024 | 363.09B |
| March 04, 2024 | 359.36B |
| March 01, 2024 | 362.65B |
| February 29, 2024 | 357.59B |
| February 28, 2024 | 361.04B |
| February 27, 2024 | 362.79B |
| February 26, 2024 | 362.47B |
| February 23, 2024 | 361.20B |
| February 22, 2024 | 358.83B |
| February 21, 2024 | 355.99B |
| February 20, 2024 | 357.06B |
| February 16, 2024 | 360.14B |
| February 15, 2024 | 358.55B |
| February 14, 2024 | 354.71B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.05B
Minimum
Mar 23 2020
375.07B
Maximum
Apr 08 2022
265.35B
Average
280.87B
Median
May 21 2021
Enterprise Value Benchmarks
| Amgen Inc | 198.03B |
| Immunogen Inc (DELISTED) | -- |
| Johnson & Johnson | 360.21B |
| Eli Lilly and Co | 711.57B |
| Merck & Co Inc | 359.08B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 822.00M |
| Revenue (Quarterly) | 14.30B |
| Total Expenses (Quarterly) | 10.82B |
| EPS Diluted (Quarterly) | 0.46 |
| Gross Profit Margin (Quarterly) | 60.11% |
| Profit Margin (Quarterly) | 5.75% |
| Earnings Yield | 1.66% |
| Operating Earnings Yield | 4.63% |
| Normalized Earnings Yield | 1.895 |